Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.63 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | CES1 | P23141 | 4/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL106861 | 0.97 | SLC22A1 (0.67) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL16343940 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL21372575 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Bicarbonate SCHEMBL28716225 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL3488443 | 0.92 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL3488441 | 0.92 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL16093909 | 0.92 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5786096 | 0.92 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5786097 | 0.92 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Bicarbonate SCHEMBL20984990 | 0.92 | SLC22A1 (0.65) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250162993-A1 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | THE JOHNS HOPKINS UNIVERSITY | 2025-05-22 | — | — | US | claimed |
| EP-3481804-B1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL | UNIV JOHNS HOPKINS (US) | 2024-11-27 | — | — | EP | claimed |
| US-11851407-B2 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL | THE JOHNS HOPKINS UNIVERSTY (US) | 2023-12-26 | — | — | US | claimed |
| US-20220055991-A1 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | THE JOHNS HOPKINS UNIVERSTY | 2022-02-24 | — | — | US | claimed |
| EP-3481437-B1 | PRECURSORS FOR RADIOFLUORINATION | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2022-01-26 | — | — | EP | claimed |
| US-20210140096-A1 | GRAPHENE MATERIAL COATING AND PREPARATION METHOD THEREOF, AIR FILTRATION DEVICE AND SYSTEM | HUBEI HIGHLAND GRAPHENE TECHNOLOGY CO., LTD. (CN) | 2021-05-13 | — | — | US | claimed |
| US-10759760-B2 | Precursors for radiofluorination | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2020-09-01 | — | — | US | claimed |
| CN-111362828-A | A kind of18F-labeled fluoropropionylated ornithine as well as preparation method and application thereof | 山西医科大学 | 2020-07-03 | — | — | CN | claimed |
| US-20200080979-A1 | METHOD AND DEVICES FOR THE SPECTROPHOTOMETRIC DETERMINATION OF RESIDUAL PHASE TRANSFER CATALYST IN A PET RADIOPHARMACEUTICAL DOSE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2020-03-12 | — | — | US | claimed |
| US-20190263756-A1 | PRECURSORS FOR RADIOFLUORINATION | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2019-08-29 | — | — | US | claimed |
| US-20190177275-A1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-06-13 | — | — | US | claimed |
| EP-3481437-A1 | PRECURSORS FOR RADIOFLUORINATION | ABX Advanced Biochemical Compounds GmbH (DE) | 2019-05-15 | — | — | EP | claimed |
| EP-3481804-A1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL | The Johns Hopkins University (US) | 2019-05-15 | — | — | EP | claimed |
| WO-2017214470-A1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-12-14 | — | — | WO | claimed |
| EP-2336114-B1 | PROCESS FOR THE SYNTHESIS OF L-3,4 DIHYDROXY-6-[18F]FLUORO-PHENYLALANINE AND 2-[18F]FLUOR-L-TYROSINE AND THEIR ALPHA-METHYLATED DERIVATIVES STARTING FROM A PRECURSOR | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2013-04-17 | — | — | EP | claimed |
| US-6919475-B2 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | Forschungszentrum Jülich GmbH (DE) | 2005-07-19 | — | — | US | claimed |
| EP-1392650-B1 | PROTECTED TYROSINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME FOR PRODUCING O-(2- ?18 F]-FLUOROETHYL)-L-TYROSINE | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2005-03-02 | — | — | EP | claimed |
| US-20040192954-A1 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | FORSCHUNGSZENTRUM GMBH (DE) | 2004-09-30 | — | — | US | claimed |
| US-5693599-A | Flux washing agent | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1997-12-02 | — | — | US | claimed |
| US-20260124326-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | GE HEALTHCARE LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4039760-B1 | POLISHING COMPOSITION | FUJIMI INC (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4717720-A1 | CATALYST COMPOSITION, BLOCKED POLYISOCYANATE COMPOSITION, COATING MATERIAL COMPOSITION, COATING FILM, AND METHOD FOR FORMING COATING FILM | Tosoh Corporation (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-12527884-B2 | Use of cyclodextrins as a radiostabilizer | GE HEALTHCARE LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| EP-4633683-A1 | CYCLOOCTENE COMPOSITIONS AND USES THEREOF | Biogen MA Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312494-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | GE HEALTHCARE INC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20250162993-A1 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | THE JOHNS HOPKINS UNIVERSITY | 2025-05-22 | — | — | US | disclosed |
| WO-2025080839-A1 | IMPROVED RADIOSYNTHESIS OF 18F-LABELED NUCLEOSIDE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-3774698-B1 | SOLID PHASE EXTRACTION | GE HEALTHCARE LTD (GB) | 2025-02-26 | — | — | EP | disclosed |
| US-20250041859-A1 | SOLID PHASE EXTRACTION | GE HEALTHCARE LIMITED (GB) | 2025-02-06 | — | — | US | disclosed |
| EP-4497477-A2 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | The Johns Hopkins University (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024262553-A1 | CATALYST COMPOSITION, BLOCKED POLYISOCYANATE COMPOSITION, COATING MATERIAL COMPOSITION, COATING FILM, AND METHOD FOR FORMING COATING FILM | 東ソー株式会社 | 2024-12-26 | — | — | WO | disclosed |
| US-12162009-B2 | Solid phase purification | GE HEALTHCARE LIMITED (GB) | 2024-12-10 | — | — | US | disclosed |
| EP-3481804-B1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL | UNIV JOHNS HOPKINS (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240366808-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | GE HEALTHCARE LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| US-20240350683-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | GE HEALTHCARE LIMITED (GB) | 2024-10-24 | — | — | US | disclosed |
| WO-2024202500-A1 | BLOCKED POLYISOCYANATE COMPOSITION, CURING AGENT FOR AQUEOUS COATING, AQUEOUS COATING COMPOSITION, AND COATING FILM | 東ソー株式会社 | 2024-10-03 | — | — | WO | disclosed |
| EP-4404981-A1 | RADIOPHARMACEUTICAL COMPLEX FOR IMAGING AND/OR LOCALIZING PSMA POSITIVE CELLS | Scogif S.r.l. (IT) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024130105-A1 | CYCLOOCTENE COMPOSITIONS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4355368-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | GE Healthcare Limited (GB) | 2024-04-24 | — | — | EP | disclosed |
| EP-4355715-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | GE Healthcare Limited (GB) | 2024-04-24 | — | — | EP | disclosed |
| US-11851407-B2 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL | THE JOHNS HOPKINS UNIVERSTY (US) | 2023-12-26 | — | — | US | disclosed |
| CN-110461802-B | Method for producing flutemetamol | 通用电气健康护理有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230120841-A1 | CASSETTE FOR STABILISED RADIOLABELLING REACTION | GE HEALTHCARE LTD (GB) | 2023-04-20 | — | — | US | disclosed |
| WO-2023047319-A1 | RADIOPHARMACEUTICAL COMPLEX FOR IMAGING AND/OR LOCALIZING PSMA POSITIVE CELLS | SCOGIF S.R.L. (IT) | 2023-03-30 | — | — | WO | disclosed |
| US-11565257-B2 | Stabilized radiolabelling reaction | GE HEALTHCARE LIMITED (GB) | 2023-01-31 | — | — | US | disclosed |
| US-20220409752-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | GE HEALTHCARE LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| WO-2022263592-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | GE HEALTHCARE LIMITED (GB) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263594-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | GE HEALTHCARE LIMITED (GB) | 2022-12-22 | — | — | WO | disclosed |
| EP-3774697-B1 | STABILISED RADIOLABELLING REACTION | GE HEALTHCARE LTD (GB) | 2022-11-23 | — | — | EP | disclosed |
| US-20220306867-A1 | MODIFIED COATING SUBSTANCES BASED ON RMA BINDERS WITH IMPROVED ADHESION ON METAL SUBSTRATES | MANKIEWICZ GEBR. & CO. (GMBH & CO. KG) (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-4048323-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | GE Healthcare Limited (GB) | 2022-08-31 | — | — | EP | disclosed |
| EP-4039760-A1 | POLISHING COMPOSITION | Fujimi Incorporated (JP) | 2022-08-10 | — | — | EP | disclosed |
| CN-114450376-A | Polishing composition | 福吉米株式会社 | 2022-05-06 | — | — | CN | disclosed |
| US-20220118117-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | MASSACHUSETTS GEN HOSPITAL (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3983471-A1 | MODIFIED COATING SUBSTANCES BASED ON RMA BINDERS WITH IMPROVED ADHESION ON METAL SUBSTRATES | Mankiewicz Gebr. & Co. GmbH & Co. KG (DE) | 2022-04-20 | — | — | EP | disclosed |
| US-20220055991-A1 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | THE JOHNS HOPKINS UNIVERSTY | 2022-02-24 | — | — | US | disclosed |
| US-20210322582-A1 | RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUND | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2021-10-21 | — | — | US | disclosed |
| US-11078166-B2 | Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3845541-A1 | RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUND | Nihon Medi-Physics Co., Ltd (JP) | 2021-07-07 | — | — | EP | disclosed |
| US-11053200-B2 | Precursors for radiofluorination | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2021-07-06 | — | — | US | disclosed |
| EP-2994169-B1 | LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING | CANCER RESEARCH TECH LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| US-20210140096-A1 | GRAPHENE MATERIAL COATING AND PREPARATION METHOD THEREOF, AIR FILTRATION DEVICE AND SYSTEM | HUBEI HIGHLAND GRAPHENE TECHNOLOGY CO., LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| EP-3589607-B1 | A PROCESS FOR PRODUCING FLUTEMETAMOL | GE HEALTHCARE LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| WO-2021078814-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | GE HEALTHCARE LIMITED (GB) | 2021-04-29 | — | — | WO | disclosed |
| US-10947197-B2 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3774697-A1 | STABILISED RADIOLABELLING REACTION | GE Healthcare Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| EP-3774698-A1 | SOLID PHASE EXTRACTION | GE Healthcare UK Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112286000-A | Composition for forming silicon-containing resist underlayer film and pattern forming method | 信越化学工业株式会社 | 2021-01-29 | — | — | CN | disclosed |
| US-20210023558-A1 | SOLID PHASE EXTRACTION | GE HEALTHCARE LIMITED (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20210017098-A1 | STABILISED RADIOLABELLING REACTION | GE HEALTHCARE LIMITED (GB) | 2021-01-21 | — | — | US | disclosed |
| US-10894779-B2 | Process for producing flutametamol | GE HEALTHCARE LIMITED (GB) | 2021-01-19 | — | — | US | disclosed |
| US-10876007-B2 | Coating systems, use thereof for coating components and thus coated components for wind power plants | MANKIEWICZ GEBR. & CO. GMBH & CO. KG (DE) | 2020-12-29 | — | — | US | disclosed |
| US-10870763-B2 | Coating systems, use thereof for coating components and thus coated components for agricultural and construction machines | MANKIEWICZ GEBR. & CO. GMBH & CO. KG (DE) | 2020-12-22 | — | — | US | disclosed |
| US-10821194-B2 | Labelled carboxylic acids and their uses in molecular imaging | Cancer Research Technologies Limited (GB) | 2020-11-03 | — | — | US | disclosed |
| CN-111856882-A | Composition for forming silicon-containing resist underlayer film and pattern forming method | 信越化学工业株式会社 | 2020-10-30 | — | — | CN | disclosed |
| US-10759760-B2 | Precursors for radiofluorination | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2020-09-01 | — | — | US | disclosed |
| US-10738196-B2 | Coating systems, use thereof for coating components and components coated therewith for rail vehicles and aircrafts | MANKIEWICZ GEBR. & CO. GMBH & CO. KG (DE) | 2020-08-11 | — | — | US | disclosed |
| CN-111458980-A | Composition for forming silicon-containing resist underlayer film and pattern forming method | 信越化学工业株式会社 | 2020-07-28 | — | — | CN | disclosed |
| CN-111423587-A | Thermosetting silicon-containing compound, composition for forming silicon-containing film, and method for forming pattern | 信越化学工业株式会社 | 2020-07-17 | — | — | CN | disclosed |
| WO-2020146515-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | THE GENERAL HOSPITAL CORPORATION (US) | 2020-07-16 | — | — | WO | disclosed |
| CN-111208710-A | Iodine-containing thermosetting silicon-containing material, resist underlayer film-forming composition for extreme ultraviolet lithography containing the same, and pattern formation method | 信越化学工业株式会社 | 2020-05-29 | — | — | CN | disclosed |
| US-20200165204-A1 | PRECURSORS FOR RADIOFLUORINATION | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2020-05-28 | — | — | US | disclosed |
| US-20200080979-A1 | METHOD AND DEVICES FOR THE SPECTROPHOTOMETRIC DETERMINATION OF RESIDUAL PHASE TRANSFER CATALYST IN A PET RADIOPHARMACEUTICAL DOSE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2020-03-12 | — | — | US | disclosed |
| US-20200062724-A1 | A PROCESS FOR PRODUCING FLUTAMETAMOL | INTEGRITY IMPLANTS INC. | 2020-02-27 | — | — | US | disclosed |
| US-10472338-B2 | Method for producing [18F]flutemetamol | GE HEALTHCARE LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| WO-2019185932-A1 | STABILISED RADIOLABELLING REACTION | GE HEALTHCARE LIMITED (GB) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019185933-A1 | SOLID PHASE EXTRACTION | GE HEALTHCARE LIMITED (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-20190263756-A1 | PRECURSORS FOR RADIOFLUORINATION | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2019-08-29 | — | — | US | disclosed |
| US-10392344-B2 | Method for preparing fluorine-18 eluent with adjusted PH, and method for labelling fluorine-18 using same | THE ASAN FOUNDATION (KR) | 2019-08-27 | — | — | US | disclosed |
| US-20190225589-A1 | TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND REVERSED CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-07-25 | — | — | US | disclosed |
| US-20190184039-A1 | LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-06-20 | — | — | US | disclosed |
| US-20190177275-A1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-06-13 | — | — | US | disclosed |
| US-20190151483-A1 | METHODS OF MAKING 18F-LABELED PRECURSORS AND PEPTIDES, LABELED C-MET BINDING PEPTIDES, AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2019-05-23 | — | — | US | disclosed |
| EP-3481804-A1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL | The Johns Hopkins University (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3481437-A1 | PRECURSORS FOR RADIOFLUORINATION | ABX Advanced Biochemical Compounds GmbH (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20190055207-A1 | Method for Producing Flutemetamol | GE HEALTHCARE LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| WO-2018158137-A1 | A PROCESS FOR PRODUCING FLUTEMETAMOL | GE HEALTHCARE LIMITED (GB) | 2018-09-07 | — | — | WO | disclosed |
| EP-3368518-A1 | METHOD FOR PRODUCING FLUTEMETAMOL | GE Healthcare Limited (GB) | 2018-09-05 | — | — | EP | disclosed |
| US-20180112098-A1 | IMPROVED COATING SYSTEMS, USE THEREOF FOR COATING COMPONENTS AND THUS COATED COMPONENTS FOR WIND POWER PLANTS | MANKIEWICZ GEBR. & CO. GMBH & CO. KG (DE) | 2018-04-26 | — | — | US | disclosed |
| US-20180100069-A1 | IMPROVED COATING SYSTEMS, USE THEREOF FOR COATING COMPONENTS AND THUS COATED COMPONENTS FOR AGRICULTURAL AND CONSTRUCTION MACHINES | MANKIEWICZ GEBR. & CO. GMBH & CO. KG (DE) | 2018-04-12 | — | — | US | disclosed |
| US-20180094143-A1 | IMPROVED COATING SYSTEMS, USE THEREOF FOR COATING COMPONENTS AND COMPONENTS COATED THEREWITH FOR RAIL VEHICLES AND AIRCRAFTS | MANKIEWICZ GEBR. & CO. GMBH & CO. KG (DE) | 2018-04-05 | — | — | US | disclosed |
| WO-2018022603-A1 | METHODS OF MAKING 18F-LABELED PRECURSORS AND PEPTIDES, LABELED C-MET BINDING PEPTIDES, AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-02-01 | — | — | WO | disclosed |
| WO-2017214470-A1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-12-14 | — | — | WO | disclosed |
| US-9839701-B2 | Aromatic amino acid derivative and positron emission topography (PET) probe using the same | OSAKA UNIVERSITY (JP) | 2017-12-12 | — | — | US | disclosed |
| EP-2810926-B1 | METHOD FOR PREPARING FLUORINE-18 ELUENT WITH ADJUSTED PH, AND METHOD FOR LABELLING FLUORINE-18 USING SAME | ASAN FOUND (KR) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017071980-A1 | METHOD FOR PRODUCING FLUTEMETAMOL | GE HEALTHCARE LIMITED (GB) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017027870-A1 | TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND \"REVERSED\" CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20160095946-A1 | LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| WO-2016045035-A1 | METHOD FOR PREPARING GRAPHENE | 深圳粤网节能技术服务有限公司 | 2016-03-31 | — | — | WO | disclosed |
| EP-2994169-A1 | LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING | Imperial Innovations Ltd (GB) | 2016-03-16 | — | — | EP | disclosed |
| WO-2016033190-A1 | RADIOTRACER COMPOUNDS | EISAI, INC. (JP) | 2016-03-03 | — | — | WO | disclosed |
| US-20160038620-A1 | AROMATIC AMINO ACID DERIVATIVE AND POSITRON EMISSION TOPOGRAPHY (PET) PROBE USING THE SAME | NARD INSTITUTE, LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2957556-A1 | AROMATIC AMINO ACID DERIVATIVE AND POSITRON EMISSION TOPOGRAPHY (PET) PROBE UTILIZING SAME | Osaka University (JP) | 2015-12-23 | — | — | EP | disclosed |
| EP-2400992-B1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH INC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20150045548-A1 | METHOD FOR PREPARING FLUORINE-18 ELUENT WITH ADJUSTED PH, AND METHOD FOR LABELLING FLUORINE-18 USING SAME | THE ASAN FOUNDATION (KR) | 2015-02-12 | — | — | US | disclosed |
| EP-2810926-A1 | METHOD FOR PREPARING FLUORINE-18 ELUENT WITH ADJUSTED PH, AND METHOD FOR LABELLING FLUORINE-18 USING SAME | The Asan Foundation (KR) | 2014-12-10 | — | — | EP | disclosed |
| US-8865122-B2 | Methods and compositions for protein labelling | GENENTECH, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-2700635-A1 | 5-Trifluoromethylpyrazole amides having herbicidal activity | BASF SE (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-2700634-A1 | 5-difluoromethylpyrazole amides having herbicidal activity | BASF SE (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-20130216475-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8435488-B2 | Methods and compositions for protein labelling | GENENTECH, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120097549-A1 | ELECTROCHEMICAL CELL AND METHOD FOR SEPARATING CARRIER-FREE 18F-FROM A SOLUTION ON AN ELECTRODE | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2012-04-19 | — | — | US | disclosed |
| EP-2411360-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC For Biomedical Imaging Development Ltd (AU) | 2012-02-01 | — | — | EP | disclosed |
| EP-2400992-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | Genentech, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7807837-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| WO-2010108210-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD (AU) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010099273-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | GENENTECH, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-04 | — | — | US | disclosed |
| US-7507756-B2 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-24 | — | — | US | disclosed |
| EP-1373218-B9 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | ORTHO MCNEIL JANSSEN PHARM (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1373218-B1 | IMIDAZOLYL DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7265135-B2 | 2-oxy, 2-amino, and 2-thio-imidazole compounds | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
| US-6919475-B2 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | Forschungszentrum Jülich GmbH (DE) | 2005-07-19 | — | — | US | disclosed |
| US-20040192954-A1 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | FORSCHUNGSZENTRUM GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| US-20040147577-A1 | Heterocyclic compounds | BOGENSTAETTER MICHAEL (GB) | 2004-07-29 | — | — | US | disclosed |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2003-11-06 | — | — | US | disclosed |
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2003-06-12 | — | — | US | disclosed |
| US-20020198237-A1 | Heterocyclic compounds | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | disclosed |
| US-5756683-A | SULFONYLUREA HERBICIDES | NOVARTIS FINANCE CORPORATION (US) | 1998-05-26 | — | — | US | disclosed |
| US-5693599-A | Flux washing agent | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5563074-A | ANTIBODY SPECIFIC TO SULFONYLUREA HERBICIDE | CIBA-GEIGY CORPORATION (US) | 1996-10-08 | — | — | US | disclosed |
| US-5516938-A | SULFONYLUREA LINKING COMPONENT | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| US-5516928-A | REACTION OF ISOPHORONE AND HYDROGEN CYANIDE USING QUATERNARY AMMONIUM CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | disclosed |
| US-5359135-A | Detection in soil, water, air by preferential affinity to monoclonal antibodies | CIBA-GEIGY CORPORATION (US) | 1994-10-25 | — | — | US | disclosed |
| US-5359135-A | Detection in soil, water, air by preferential affinity to monoclonal antibodies | CIBA-GEIGY CORPORATION (US) | 1994-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (48 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322582-A1 | RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUND | CA9, CA4, CA14 | SLC22A1 2306/4885SLC22A2 2859/4885ALDH1A1 3630/4885 |
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | SLC22A1 912/4885SLC22A2 868/4885ALDH1A1 3392/4885 |
| US-20260124326-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | SLC7A11, BTD, PGD | SLC22A1 494/4885SLC22A2 907/4885ALDH1A1 778/4885 |
| US-10759760-B2 | Precursors for radiofluorination | QRFPR, SSTR3, IGF1R | SLC22A1 2877/4885SLC22A2 3032/4885ALDH1A1 4360/4885 |
| US-20210023558-A1 | SOLID PHASE EXTRACTION | PNN, PDXK, TYMP | SLC22A1 3282/4885SLC22A2 3263/4885ALDH1A1 2504/4885 |
| US-11078166-B2 | Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof | PAICS, FOLH1, UTS2R | SLC22A1 2887/4885SLC22A2 3175/4885ALDH1A1 3174/4885 |
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | BHMT2, MGMT, AHCY | SLC22A1 1057/4885SLC22A2 1155/4885ALDH1A1 1944/4885 |
| US-20160095946-A1 | LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING | PSAT1, SLC25A1, SLC16A7 | SLC22A1 176/4885SLC22A2 126/4885ALDH1A1 2719/4885 |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | SLC22A1 505/4885SLC22A2 506/4885ALDH1A1 2758/4885 |
| US-20040192954-A1 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | TH, TYR, TYRO3 | SLC22A1 2489/4885SLC22A2 3060/4885ALDH1A1 1316/4885 |
| US-20190184039-A1 | LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING | SLC25A1, DNPEP, CA3 | SLC22A1 174/4885SLC22A2 118/4885ALDH1A1 2358/4885 |
| US-20210017098-A1 | STABILISED RADIOLABELLING REACTION | PDXK, MPI, PAICS | SLC22A1 2484/4885SLC22A2 2711/4885ALDH1A1 2671/4885 |
| US-20250041859-A1 | SOLID PHASE EXTRACTION | PNN, PDXK, TYMP | SLC22A1 3282/4885SLC22A2 3263/4885ALDH1A1 2504/4885 |
| US-20100221176-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | RAB5IF, RPS27A, PSMA6 | SLC22A1 3158/4885SLC22A2 3303/4885ALDH1A1 4242/4885 |
| US-20150045548-A1 | METHOD FOR PREPARING FLUORINE-18 ELUENT WITH ADJUSTED PH, AND METHOD FOR LABELLING FLUORINE-18 USING SAME | PHF8, AFF1, F8 | SLC22A1 897/4885SLC22A2 1107/4885ALDH1A1 3452/4885 |
| US-20190055207-A1 | Method for Producing Flutemetamol | ADRB3, ADRB1, ADRB2 | SLC22A1 3444/4885SLC22A2 3666/4885ALDH1A1 3367/4885 |
| US-20090143591-A1 | SCALABLE SYNTHESIS OF IMIDAZOLE DERIVATIVES | ABL1, NOS2, FLT3 | SLC22A1 4542/4885SLC22A2 4413/4885ALDH1A1 2343/4885 |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | SLC22A1 505/4885SLC22A2 506/4885ALDH1A1 2758/4885 |
| US-11565257-B2 | Stabilized radiolabelling reaction | PDXK, MPI, PAICS | SLC22A1 2855/4885SLC22A2 3116/4885ALDH1A1 2933/4885 |
| US-11053200-B2 | Precursors for radiofluorination | QRFPR, SSTR3, IGF1R | SLC22A1 2877/4885SLC22A2 3032/4885ALDH1A1 4360/4885 |
| US-10947197-B2 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL | FOLH1, KLK3, BPHL | SLC22A1 738/4885SLC22A2 900/4885ALDH1A1 2011/4885 |
| US-20240350683-A1 | PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION | PROC, CYP27B1, TTPA | SLC22A1 679/4885SLC22A2 666/4885ALDH1A1 224/4885 |
| US-20220409752-A1 | USE OF CYCLODEXTRINS AS A RADIOSTABILIZER | SLC7A11, TBCA, GYPA | SLC22A1 313/4885SLC22A2 459/4885ALDH1A1 1366/4885 |
| US-20220118117-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 4 | GRM2, GRM4, GRM1 | SLC22A1 408/4885SLC22A2 367/4885ALDH1A1 4206/4885 |
| US-20200062724-A1 | A PROCESS FOR PRODUCING FLUTAMETAMOL | ADRB3, ADRB1, PFAS | SLC22A1 3411/4885SLC22A2 3802/4885ALDH1A1 1241/4885 |
| US-20050250948-A1 | Scalable synthesis of imidazole derivatives | ABL1, NOS2, FLT3 | SLC22A1 4542/4885SLC22A2 4413/4885ALDH1A1 2343/4885 |
| US-10472338-B2 | Method for producing [18F]flutemetamol | ADRB3, ADRB1, ADRB2 | SLC22A1 3163/4885SLC22A2 3414/4885ALDH1A1 2641/4885 |
| US-10894779-B2 | Process for producing flutametamol | ADRB3, ADRB1, ADRA1B | SLC22A1 3363/4885SLC22A2 3737/4885ALDH1A1 1386/4885 |
| US-20190151483-A1 | METHODS OF MAKING 18F-LABELED PRECURSORS AND PEPTIDES, LABELED C-MET BINDING PEPTIDES, AND METHODS OF USE THEREOF | MET, MYCBP, METTL14 | SLC22A1 810/4885SLC22A2 883/4885ALDH1A1 3909/4885 |
| US-20020198237-A1 | Heterocyclic compounds | HRH2, HRH4, HRH1 | SLC22A1 4331/4885SLC22A2 4237/4885ALDH1A1 1526/4885 |
| US-20220055991-A1 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | FOLH1, KLK3, BPHL | SLC22A1 738/4885SLC22A2 900/4885ALDH1A1 2011/4885 |
| US-20230120841-A1 | CASSETTE FOR STABILISED RADIOLABELLING REACTION | PAICS, MPI, PDXK | SLC22A1 1309/4885SLC22A2 1699/4885ALDH1A1 2038/4885 |
| US-20160038620-A1 | AROMATIC AMINO ACID DERIVATIVE AND POSITRON EMISSION TOPOGRAPHY (PET) PROBE USING THE SAME | SLC7A1, SLC43A1, LATS1 | SLC22A1 64/4885SLC22A2 125/4885ALDH1A1 2352/4885 |
| US-20250312494-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | AQP1, AQP3, TMEM14C | SLC22A1 2282/4885SLC22A2 2410/4885ALDH1A1 3162/4885 |
| US-20190177275-A1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | KLK3, FOLH1, BPHL | SLC22A1 1018/4885SLC22A2 1172/4885ALDH1A1 2167/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | SLC22A1 912/4885SLC22A2 868/4885ALDH1A1 3392/4885 |
| US-10821194-B2 | Labelled carboxylic acids and their uses in molecular imaging | SLC25A1, DNPEP, CA3 | SLC22A1 174/4885SLC22A2 118/4885ALDH1A1 2358/4885 |
| US-20130216475-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELLING | RAB5IF, RPS27A, PSMA6 | SLC22A1 3158/4885SLC22A2 3303/4885ALDH1A1 4242/4885 |
| US-10392344-B2 | Method for preparing fluorine-18 eluent with adjusted PH, and method for labelling fluorine-18 using same | PHF8, AFF1, F8 | SLC22A1 897/4885SLC22A2 1107/4885ALDH1A1 3452/4885 |
| US-20040147577-A1 | Heterocyclic compounds | HRH2, HRH4, HRH1 | SLC22A1 4331/4885SLC22A2 4237/4885ALDH1A1 1526/4885 |
| US-20190263756-A1 | PRECURSORS FOR RADIOFLUORINATION | QRFPR, SSTR3, IGF1R | SLC22A1 2877/4885SLC22A2 3032/4885ALDH1A1 4360/4885 |
| US-20250162993-A1 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | FOLH1, KLK3, BPHL | SLC22A1 766/4885SLC22A2 938/4885ALDH1A1 1969/4885 |
| US-20240366808-A1 | METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP | AQP1, AQP3, TMEM14C | SLC22A1 2375/4885SLC22A2 2485/4885ALDH1A1 3147/4885 |
| US-20190225589-A1 | TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND REVERSED CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF | PAICS, FOLH1, UTS2R | SLC22A1 2887/4885SLC22A2 3175/4885ALDH1A1 3174/4885 |
| US-12527884-B2 | Use of cyclodextrins as a radiostabilizer | BTD, SLC7A11, PGD | SLC22A1 501/4885SLC22A2 884/4885ALDH1A1 898/4885 |
| US-20200165204-A1 | PRECURSORS FOR RADIOFLUORINATION | QRFPR, SSTR3, IGF1R | SLC22A1 2877/4885SLC22A2 3032/4885ALDH1A1 4360/4885 |
| US-11851407-B2 | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL | FOLH1, KLK3, BPHL | SLC22A1 738/4885SLC22A2 900/4885ALDH1A1 2011/4885 |
| US-12162009-B2 | Solid phase purification | PDXK, PNN, TYMP | SLC22A1 3112/4885SLC22A2 3118/4885ALDH1A1 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.